Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fulcrum Therapeutics
Biotech
Slate uses Fulcrum to join Nasdaq with $245M for migraine trials
Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth.
Nick Paul Taylor
Aug 17, 2026 9:30am
Fulcrum scraps SCD plan as FDA takes hard line on safety risks
Jun 2, 2026 8:46am
BMS' MyoKardia scraps heart muscle pact with Fulcrum
Mar 5, 2025 5:30am
Sanofi's $80M bet on Fulcrum dystrophy drug ends in phase 3 fail
Sep 12, 2024 9:30am
Sanofi pays Fulcrum $80M for rights to phase 3 rare disease drug
May 13, 2024 7:09am
Bayer undergoes leadership shake-up—Chutes & Ladders
Mar 22, 2024 9:30am
